poisar

Stocks · News reference

Ensysce Biosciences Reports Third Quarter 2026 Financial and Operational Results

Fiscal.ai

Ensysce Biosciences announced its financial results for the third quarter ended September 30, 2026, highlighting the impact of its recent Cy Biopharma acquisition and progress in its clinical pipeline.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Fiscal.ai

    Ensysce Biosciences Announces CEO Transition

    Ensysce Biosciences announced that CEO Lynn Kirkpatrick will transition to the role of Chief Operating Officer, with President James Morrisson set to assume the CEO position following the company's annual meeting on December 14, 2026.